Ultime notizie per Humana (NYSE:HUM) Azioni

HUMANA INC

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Deep-pocketed investors have adopted a bearish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 58% bearish. Among these notable options, 6 are puts, totaling $210,195, and 6 are calls, amounting to $257,020.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $180.0 and $255.0 for Humana, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Humana's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Humana's whale trades within a strike price range from $180.0 to $255.0 in the last 30 days. 
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751997651_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$19.4</td>
<td>$18.9</td>
<td>$19.3</td>
<td>$240.00</td>
<td>$106.1K</td>
<td align="right">690</td>
<td align="right">79</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$4.5</td>
<td>$4.2</td>
<td>$4.5</td>
<td>$237.50</td>
<td>$45.0K</td>
<td align="right">223</td>
<td align="right">217</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.6</td>
<td>$22.5</td>
<td>$22.6</td>
<td>$250.00</td>
<td>$40.6K</td>
<td align="right">204</td>
<td align="right">19</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$237.50</td>
<td>$35.0K</td>
<td align="right">161</td>
<td align="right">109</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$23.3</td>
<td>$23.1</td>
<td>$23.1</td>
<td>$240.00</td>
<td>$34.6K</td>
<td align="right">4</td>
<td align="right">16</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Trading volume stands at 417,881, with HUM's price down by 0.0%, positioned at $237.21.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $269.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Humana, which currently sits at a price target of $260. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Humana, targeting a price of $280. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $268. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Humana's Options: A Look at What the Big Money is Thinking

Managed care insurers have faced a turbulent few months, with several major players experiencing steep market capitalization losses amid earnings uncertainty and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">looming policy shifts</a>.
<h2 class="wp-block-heading">UnitedHealth Leads The Downturn Amidst Guidance Withdrawal And CEO Resignation</h2>
UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) led the downturn with a staggering 40.9% drop in market cap in the second quarter and a 39.6% decline year over year, triggered largely by its decision to withdraw 2025 earnings guidance.
UnitedHealth&#8217;s CEO, Andrew Witty, resigned for personal reasons, and the previous CEO, Stephen Hemsley, succeeded him. The company also <a target="_blank" href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" rel="noreferrer noopener">withdrew 2025 guidance</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
Despite the significant drop, UnitedHealth retained its top spot as the largest U.S. insurer, with a market cap of $283 billion, well ahead of second-ranked The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), which stood at $156.44 billion.
<h2 class="wp-block-heading">Managed Care Suffers While Property And Casualty Gains</h2>
An analysis by S&amp;P Global of the 20 largest U.S. insurers by market capitalization highlighted a sharp divide between segments.
Among the eight companies that saw market cap declines of more than 5%, half were managed care firms. In contrast, five of the six insurers with gains were property and casualty providers, reflecting stronger investor confidence in that sector.
<h2 class="wp-block-heading">Ripple Effect: Other Health Insurers Follow Suit</h2>
Other health insurers followed UnitedHealth&#8217;s downward trajectory. Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) saw its market cap drop 10.3% in the second quarter, while Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) declined 10.8%. Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) posted more modest losses of 7.6% and 1%, respectively.
<h2 class="wp-block-heading">Third-Quarter Woes Intensify With Policy Uncertainty</h2>
The pressure has extended into the third quarter. Last week, Centene also <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46222916/centenes-guidance-withdrawal-spooks-sector-oscar-health-stock-falls" rel="noreferrer noopener">withdrew its 2025 guidance</a>, sending the market into shock. The result was a 40.37% stock plunge in a single day. The fallout also affected peers, with UnitedHealth and Elevance falling 5.7% and 11.5%, respectively.
Investor sentiment was further rattled by President Donald Trump&#8217;s proposed One Big Beautiful Bill Act, which appears close to congressional approval.
The S&amp;P <a target="_blank" href="https://www.spglobal.com/market-intelligence/en/news-insights/articles/2025/7/unitedhealth-remains-largest-us-insurer-by-market-cap-after-40-hit-in-q2-2025-91405077" rel="noreferrer noopener">report</a> added that the legislation could significantly impact Medicaid access, a key business area for managed care insurers like UnitedHealth and Centene that administer the program through government funding. The policy risk triggered another selloff in the first week of the third quarter.
<h2 class="wp-block-heading">Broader Insurance Industry Shows Resilience</h2>
Still, the broader insurance industry has shown resilience. At the end of the second quarter, the S&amp;P 500 insurance index climbed 19.55% year over year, surpassing the S&amp;P 500&#8217;s 15.16% gain during the same period.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46192421/home-health-braces-for-potential-1-billion-cut-in-medicare-payments" target="_blank" rel="noreferrer noopener">Home Health Braces For Potential $1 Billion Cut In Medicare Payments</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Large Cap

News

Health Care

Movers

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

UnitedHealth, Centene Hit Hard By Guidance Shock, Trump's Medicaid Push

Reported Thursday, Humana's CenterWell To Acquire The Villages Health Assets Amid Strategic Bankruptcy Filing

WIIM

Shares of health insurance stocks are trading lower in sympathy with Centene, which withdrew its 2025 guidance.

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

ALHC

CLOV

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

<a href="https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19">https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19</a>

ELEV

'Lawmakers Seek to Close VA Loophole That Funnels Billions to Private Medicare Insurers'- WSJ

Whales with a lot of money to spend have taken a noticeably bullish stance on Humana.
Looking at options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $84,926 and 6, calls, for a total amount of $1,517,276.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $170.0 to $380.0 for Humana during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $170.0 to $380.0 over the preceding 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750701840_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.9</td>
<td>$13.4</td>
<td>$13.6</td>
<td>$250.00</td>
<td>$1.3M</td>
<td align="right">173</td>
<td>1.0K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$23.2</td>
<td>$20.6</td>
<td>$22.43</td>
<td>$260.00</td>
<td>$45.1K</td>
<td align="right">33</td>
<td>20</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$83.6</td>
<td>$82.5</td>
<td>$83.6</td>
<td>$170.00</td>
<td>$33.4K</td>
<td align="right">15</td>
<td>4</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$106.1</td>
<td>$99.0</td>
<td>$103.26</td>
<td>$340.00</td>
<td>$30.9K</td>
<td align="right">0</td>
<td>3</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$146.3</td>
<td>$137.4</td>
<td>$142.24</td>
<td>$380.00</td>
<td>$28.4K</td>
<td align="right">2</td>
<td>2</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Having examined the options trading patterns of Humana, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 711,531, with HUM's price down by -0.22%, positioned at $239.09.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $270.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Humana with a target price of $280. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Humana, targeting a price of $268. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Humana, which currently sits at a price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $273. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Looking At Humana's Recent Unusual Options Activity

B of A Securities analyst Kevin Fischbeck maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $320 to $260.

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on Humana, Lowers Price Target to $260

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $305 to $280.

Truist Securities Maintains Hold on Humana, Lowers Price Target to $280

<a href="https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true</a>

EHTH

GOCO

'Senate Republicans to Omit Medicare Advantage Cuts in Tax Bill'- Bloomberg

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $273 to $268.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $268

Humana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has risen 11.11% since its last report. The company recently reported that it has 3.44 million shares sold short, which is 3.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Humana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749499218_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Humana has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 4.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Humana Gaining or Losing Market Support?

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) signaled support for reforms that would curb industry billing practices that have led to billions <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in additional payments</a>.
What Happened: Last fall, Senators Mike Crapo and Ron Wyden asked insurers for ideas to address home-visit-related payment practices. 
Human, one of the largest Medicare Advantage insurers in the U.S., recently shared its stance. In a one-page policy overview viewed by The Wall Street Journal, the company favored limiting insurers&#8217; use of home visit diagnoses to obtain higher payments.
These home visits, often conducted by nurse practitioners and not directly linked to treatment, have become increasingly scrutinized for their role in boosting payments by identifying sometimes questionable or unverified medical conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
Why It Matters: Humana&#8217;s position is a notable shift in the ongoing debate over payments tied to diagnosis coding in the $460 billion Medicare Advantage program.
A Wall Street Journal investigation <a target="_blank" href="https://www.wsj.com/health/healthcare/medicare-billing-changes-humana-6f20c05b" rel="noreferrer noopener">revealed</a> that such home-based assessments generated $15 billion in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45108509/humana-does-not-alter-2025-outlook-despite-sales-miss-and-medicare-membership-decline" rel="noreferrer noopener">additional revenue for Medicare</a> Advantage insurers between 2019 and 2021.
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) accounted for roughly two-thirds of those payments, with an average gain of $2,735 per home visit. Humana&#8217;s average was $1,525.
UnitedHealth&#8217;s HouseCalls program conducted around 2.9 million home visits last year, while CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), through Signify Health, also operates a similar model.
Insurers argue that many of these home visits help detect undiagnosed conditions. However, reports indicate that diagnoses are frequently recorded by nurses who aren&#8217;t treating the conditions and may rely on broad training to spot potential health issues.
These diagnoses often don&#8217;t align with those documented by the patients&#8217; primary care physicians.
Humana has proposed that insurers should only receive extra payments for diagnoses made during home visits if those conditions are documented during other types of medical encounters, such as health-risk assessments outside the home or standard clinic visits.
The company also recommends limiting another controversial practice: diagnosis coding from medical chart reviews unrelated to specific patient visits. Humana&#8217;s policy update comes after an internal review launched by CEO Jim Rechtin, who took the helm in July 2023.
Meanwhile, Medicare&#8217;s top official, Mehmet Oz, has committed to tightening oversight of the Advantage program.
Legal Issues: In May, the U.S. Department of Justice filed a lawsuit against <a href="https://www.benzinga.com/general/health-care/25/04/44927473/despite-medicaid-pressure-elevance-health-delivers-strong-q1-performance-reiterates-profit-outlook" target="_blank" rel="noreferrer noopener">Elevance Health, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana, and Aetna, Inc. 
The lawsuit alleges that from 2016 through at least 2021, the insurers paid hundreds of millions of dollars in illegal kickbacks to brokers in exchange for enrolling Medicare beneficiaries into their <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45202124/humana-elevance-aetna-face-doj-lawsuit-over-illegal-kickback-scheme-discrimination-against-disabled-people" rel="noreferrer noopener">Medicare Advantage plans</a>.
And in February, the Justice Department launched a civil fraud investigation into UnitedHealth&#8217;s <a href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" target="_blank" rel="noreferrer noopener">Medicare billing practices</a>.
The probe examines UnitedHealth's Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Price Action: HUM stock is up 0.29% at $231.88 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45791411/procter-gamble-to-eliminate-7000-roles-divest-brands-in-new-restructuring-strategy" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble To Eliminate 7,000 Roles, Divest Brands In New Restructuring Strategy</a></li>
</ul>
Image: Shutterstock

Humana Backs Reforms To Limit Medicare Advantage Billing Practices

Agreement Expanded for Additional Five Years
PALM BEACH GARDENS, Fla., June 3, 2025 /PRNewswire/ -- Longevity Health, a clinical services company and national Institutional Special Needs Plan (ISNP), today announced that it has extended its partnership with Humana through 2030.
Launched in 2023, the Humana/Longevity collaboration expands special needs health plan offerings for Medicare-eligible individuals living in skilled nursing and senior living facilities. The collaboration between the two companies currently serves members in seven states, and there are plans for significant expansion of new markets, solutions, customer segments and members served.

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Extends Strategic Partnership With Humana Through 2030 To Expand Special Needs Medicare Plan Offerings Across Skilled Nursing And Senior Living Facilities, With Plans For Multi-State Growth And Broader Member Reach

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, a high estimate of $326.00, and a low estimate of $273.00. Witnessing a positive shift, the current average has risen by 3.69% from the previous average price target of $296.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748887257_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$273.00</td>
<td>$322.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$305.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$322.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$325.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$326.00</td>
<td>-</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$316.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Humana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Humana's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Humana's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.45% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.87%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 2.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Humana

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $322 to $273.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $273

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share ("EPS") or approximately $16.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2025 ("FY 2025"). This guidance is consistent with the guidance issued in the Company's press release dated April 30, 2025.
 &nbsp;

Guidance

Humana Reaffirms FY25 Guidance Of $14.68 EPS And $16.25 Adj EPS

Financing

Humana Enters Into $5B Unsecured Revolving Credit Agreement; Agreement Permits Up To $1B Of Incremental Commitments; New Agreement Replaces Existing $2.1B Credit Agreement

Comments

Humana

Notizie

Ultime notizie per Humana (NYSE:HUM) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO